Levetiracetam for treatment of neonatal seizures.

Abstract

Neonatal seizures are often refractory to treatment with initial antiseizure medications. Consequently, clinicians turn to alternatives such as levetiracetam, despite the lack of published data regarding its safety, tolerability, or efficacy in the neonatal population. We report a retrospectively identified cohort of 23 neonates with electroencephalographically confirmed seizures who received levetiracetam. Levetiracetam was considered effective if administration was associated with a greater than 50% seizure reduction within 24 hours. Levetiracetam was initiated at a mean conceptional age of 41 weeks. The mean initial dose was 16 ± 6 mg/kg and the mean maximum dose was 45 ± 19 mg/kg/day. No respiratory or cardiovascular adverse effects were reported or detected. Levetiracetam was associated with a greater than 50% seizure reduction in 35% (8 of 23), including seizure termination in 7. Further study is warranted to determine optimal levetiracetam dosing in neonates and to compare efficacy with other antiseizure medications.

• Authors: Nicholas S Abend, Ana M Gutierrez-Colina, Heather M Monk, Dennis J Dlugos, Robert R Clancy
• Journal: Journal of child neurology (J Child Neurol) Vol. 26 Issue 4 Pg. 465-70 (Apr 2011) ISSN: 1708-8283 [Electronic] United States
• PMID: 21233461 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Anticonvulsants
• Levetiracetam
• Piracetam

Topics

• Anticonvulsants (therapeutic use)
• Child, Preschool
• Electroencephalography (methods)
• Female
• Gestational Age
• Humans
• Levetiracetam
• Male
• Piracetam (analogs & derivatives, therapeutic use)
• Retrospective Studies
• Seizures (drug therapy)
• Treatment Outcome